GoodRx (NASDAQ:GDRX) Shares Gap Up - Here's Why

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $4.76, but opened at $4.92. GoodRx shares last traded at $4.86, with a volume of 39,870 shares.

Analyst Upgrades and Downgrades

GDRX has been the topic of a number of recent analyst reports. UBS Group lowered their target price on GoodRx from $9.00 to $8.50 and set a "neutral" rating on the stock in a research note on Friday, August 9th. Citigroup dropped their target price on shares of GoodRx from $10.00 to $7.00 and set a "buy" rating on the stock in a research note on Wednesday, November 13th. Royal Bank of Canada restated an "outperform" rating and set a $10.00 price target on shares of GoodRx in a research note on Friday, August 16th. Barclays dropped their price objective on GoodRx from $10.00 to $6.00 and set an "overweight" rating on the stock in a research note on Monday, November 11th. Finally, Raymond James raised GoodRx from an "outperform" rating to a "strong-buy" rating and set a $10.00 target price for the company in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating, four have given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, GoodRx presently has an average rating of "Moderate Buy" and an average price target of $8.86.

GoodRx Price Performance

The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $1.84 billion, a P/E ratio of -161.33, a P/E/G ratio of 3.54 and a beta of 1.39. The business's fifty day moving average price is $5.98 and its 200-day moving average price is $7.25.

Insider Transactions at GoodRx

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total value of $83,921.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 4.17% of the company's stock.

Hedge Funds Weigh In On GoodRx

Several institutional investors have recently modified their holdings of the business. Liontrust Investment Partners LLP acquired a new position in shares of GoodRx during the second quarter worth about $520,000. Raymond James & Associates grew its holdings in GoodRx by 212.6% during the 3rd quarter. Raymond James & Associates now owns 394,006 shares of the company's stock worth $2,734,000 after acquiring an additional 267,951 shares in the last quarter. Legato Capital Management LLC purchased a new stake in shares of GoodRx in the 2nd quarter valued at approximately $805,000. Marshall Wace LLP acquired a new stake in shares of GoodRx in the 2nd quarter valued at $843,000. Finally, Rubric Capital Management LP lifted its position in shares of GoodRx by 76.5% during the 2nd quarter. Rubric Capital Management LP now owns 3,736,802 shares of the company's stock worth $29,147,000 after purchasing an additional 1,619,748 shares during the last quarter. Institutional investors and hedge funds own 63.77% of the company's stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.